Dopamine agonists

Important! You should always read carefully the information leaflet that comes with your medication before you start using it. Always check with your doctor or other healthcare professional before altering any of your medications or taking over-the-counter medications as they can interfere with Parkinson’s medications and may have unwanted side effects. Remember also to tell your doctor if you take over-the-counter drugs that can be bought without a prescription.


What you should know about your medication

Each medication has its own particular properties and important considerations to be aware of. Below are some key aspects to think about before you start taking your medication. Detailed information regarding these can be found in the Patient Information Leaflet (PIL):

  • what is it and what is it used for?
  • special warnings and precautions
  • how to take it
  • possible side effects
  • contraindications (when not to use it)
  • interaction with other medication(s)
  • what to do if you forget to take a dose
  • what to do if you take more than you should
  • possible effects on your ability to drive or use machinery
  • safety in pregnancy and breast-feeding
  • how to store.

 

Parkinson's medication overview
Generic name Brand name ®

Dopamine agonists [oral]

  • Bromocriptine
  • Cabergoline
  • Lisuride
  • Pergolide
  • Pramipexole
  • Ropinirole
  • Parlodel
  • Cabaser
  • Revanil
  • Celance
  • Mirapexin/Sifrol
  • Requip

Dopamine agonists [transdermal]

  • Rotigotine
  • Neupro

Dopamine agonists [subcutaneous]

  • Apomorphine
  • Apo-go
  • Dacepton

Dopamine agonist s [oral]

Cabaser® is used to treat the symptoms of Parkinson’s. It is used after your doctor has tried other treatments that have not worked or for people who are already taking other medicines for this condition to help control other symptoms.

This medicine contains cabergoline which acts in a similar way to a chemical in the body called dopamine. People with Parkinson’s do not have enough of this chemical.

Cabergoline belongs to a group of medicines called dopamine agonists.

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on Cabaser®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website.

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

Mirapexin®/Sifrol® contain the active substance pramipexole and belong to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain. Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements.

Mirapexin®/Sifrol® is used to:

  • treat the symptoms of primary Parkinson’s in adults. It can be used alone or in combination with levodopa (another medicine for Parkinson’s).
  • treat the symptoms of moderate to severe primary Restless Legs Syndrome in adults. 

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on Mirapexin®/Sifrol®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website.

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

European Public Assessment Report (EPAR)           

EPARs are full scientific assessment reports of medicines authorised at a European Union level

Links below go to the European Medicines Agency (EMA) website. The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.

The EMA publishes an EPAR for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP). EPARs are full scientific assessment reports of medicines authorised at a European Union level. 

ReQuip® and ReQuip XL® are used to treat Parkinson’s. The active ingredient in ReQuip® is ropinirole, which belongs to a group of medicines called dopamineagonists. Dopamine agonists affect the brain in a similar way to a natural substance called dopamine.

People with Parkinson’s disease have low levels of dopamine in some parts of their brains. Ropinirole has effects similar to those of natural dopamine, so it helps to reduce the symptoms of Parkinson’s.

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on ReQuip®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website.

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

Dopamine agonists [transdermal]

Neupro® belongs to a group of medicines called dopamine agonists which stimulate a certain type of cells that bind with dopamine receptors in the brain.

Neupro® is used to treat the signs and symptoms of Parkinson’s disease either alone or in combination with the medicine called levodopa.

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on Neupro®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website.

 Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

 European Public Assessment Report (EPAR)                                

EPARs are full scientific assessment reports of medicines authorised at a European Union level.

Links below go to the European Medicines Agency (EMA) website. The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.

The EMA publishes an EPAR for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP). EPARs are full scientific assessment reports of medicines authorised at a European Union level. 

Dopamine agonists [subcutaneous]

Apomorphine hydrochloride belongs to a group of medicines known as dopamine agonists which are used to treat Parkinson’s. It helps to reduce the amount of time spent in an ‘off’ or immobile state in people who have previously been treated for Parkinson’s with levodopa and/or other dopamine agonists. Your doctor or nurse will help you recognise the signs of when you need to use your medicine.

Apomorphine is administered as a solution using an injectable pen OR via a catheter using a small, portable pump system. It is injected into the area under the skin (subcutaneous).

Despite the name, apomorphine does not contain morphine.

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on APO-go®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC)or the Medicines and Healthcare Products Regulatory Agency (MHRA) website.

Further reading

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

Back to top